Compositions and methods for regenerative therapy using IPSC-derived endothelial cells in microgels

By creating anisotropic microgels with aligned fibrillar structures and interconnected channels, the method addresses the limitations of hydrogels in vascularization and cellular alignment, improving tissue repair and regeneration.

WO2026236523A1PCT designated stage Publication Date: 2026-11-12CEDARS SINAI MEDICAL CENT +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027144
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

Smart Images

  • Figure US2026027144_12112026_PF_FP_ABST
    Figure US2026027144_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are methods of producing a modular composition with patterned cells (e.g., iECs), compositions comprising cells embedded in a modular composition with patterned cells, and methods of treating diseases and conditions.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS AND METHODS FOR REGENERATIVE THERAPY USING IPSC- DERIVED ENDOTHELIAL CELLS IN MICROGELSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application includes a claim of priority under 35 U.S.C. §119(e) to U.S. provisional patent application No. 63 / 803,064, filed May 9, 2025, the entirety of which is hereby incorporated by reference.FIELD OF INVENTION

[0002] This invention relates to vascularization strategies using iPSC-derived endothelial cells incorporated in microgels for regenerative medicine.BACKGROUND

[0003] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

[0004] Hydrogels have been utilized extensively in many biomedical applications, such as in 3D cell culture and tissue engineering. Despite their biomimetic properties, hydrogels exhibit limitations as injectable materials for cell delivery, primarily due to their nanoporosity, which restricts diffusion and hinders effective tissue infiltration and vascular ingrowth. Thus, microfabricated hydrogels have been increasingly used for tissue engineering as they can be made to have higher surface area to volume ratios to enhance cell infiltration and vascular formation after implantation compared to bulk counter parts.

[0005] In the body, cells reside in a complex niche that regulates their functions. For example, cellular alignment, which is crucial in various tissues like heart, muscle, and nerve, is regulated by extracellular matrix (ECM) fibers. In 2D culture substrates, cells can be induced to align using microarchitectural control, mechanical stimulation, or aligned ECM. Control of cellular arrangement in 3D hydrogels is often not well structured due to isotropic environment for cells. Some control on dictating cellular behavior can be achieved by utilizing microfabricated hydrogels such as microgels, in which cells tend to align within microgels by4916-7926-95402 Page 1 of 47 065472-001029WOPTpulling on their surroundings. However, in these cases the nanofibrous polymers are often randomly oriented with no inherent anisotropic properties.

[0006] Material anisotropic properties in hydrogels can be generated by aligning polymer networks inside the hydrogels. Conventional approaches such as strain induced cellular alignment, fiber reinforced cellular alignment, utilization of anisogels, and other external stimulation driven approaches have been used to direct cellular response in 3D environment. However, such methodologies are complex and not scalable. Shape induced anisotropy in microgels can be achieved using microfluidics, however the control on such alignment is limited. Recently, microgel-based granular hydrogels have garnered significant attention for their potential in tissue repair and regeneration applications. The majority of microgels have been synthesized using techniques such as microfluidics, emulsion processes, and fragmentation methods. However, these approaches have notable limitations, particularly in their inability to control or influence the internal architecture of the microgels.

[0007] As such, there remains a need in the art for vascularization strategies using iPSC-derived endothelial cells incorporated in microgels for regenerative medicine.SUMMARY OF THE INVENTION

[0008] The following embodiments and aspects thereof are described and illustrated in conjunction with compositions and methods which are meant to be exemplary and illustrative, not limiting in scope.

[0009] Various embodiments provide for a method of producing a modular composition with patterned cells, comprising: providing a hydrogel composition having aligned fibrillar structures, interconnected channels and modular scaffolds; seeding cells of a first cell type onto the modular scaffolds of the hydrogel composition; adding additional cell culture medium to the hydrogel composition; and culturing the cells of the first cell type in the hydrogel composition to generate the modular composition with patterned cells.

[0010] In various embodiments, the hydrogel composition can further comprise cells of a second cell type embedded in micromodules in the hydrogel composition.

[0011] In various embodiments, the method can further comprise seeding cells of a second cell type in micromodules in the hydrogel composition.

[0012] In various embodiments, seeding cells of the first cell type can comprise seeding the cells of the first cell type at a density of about 10,000-1,000,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type can comprise seeding the cells of the first cell type at a density of about 25,000-500,000 cells per 10 ml cell culture4916-7926-95402 Page 2 of 47 065472-001029WOPTmedium. In various embodiments, seeding cells of the first cell type can comprise seeding the cells of the first cell type at a density of about 50,000-150,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type can comprise seeding the cells of the first cell type at a density of about 100,000 cells per 10 ml cell culture medium. In various embodiments, the cell culture medium can be differentiation medium.

[0013] In various embodiments, the adding additional cell culture medium to the hydrogel composition can comprise adding the additional cell culture medium after about 10-120 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition can comprise adding the additional cell culture medium after about 15-60 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition can comprise adding the additional cell culture medium after about 30 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the additional cell culture medium can be differentiation medium.

[0014] In various embodiments, seeding cells of the first cell type onto the hydrogel composition can comprise adding endothelial cells derived from induced pluripotent stem cells (iECs) to the hydrogel composition a drop-wise manner at a density of about 100,000 cells per 10 ml in iEC differentiation medium; adding additional cell culture medium to the hydrogel composition can comprise adding additional iEC differentiation medium after about 30 minutes; and the hydrogel composition is a hydrogel sheet comprising interconnected channels.

[0015] In various embodiments, the cells of the first cell type can be iPSC, endothelial cells derived from induced pluripotent stem cells (iECs), islet cells, smooth muscle cells, or pericytes. In various embodiments, the cells of the first cell type can be endothelial cells derived from induced pluripotent stem cells (iECs).

[0016] In various embodiments, the interconnected channels can have 50-800 pm dimensions. In various embodiments, the interconnected channels can have 100-600 pm dimensions. In various embodiments, the interconnected channels can have 200-400 pm dimensions.

[0017] In various embodiments, the cells of the first cell type can grow in the interconnected channels. In various embodiments, the cells of the first cell type can restrict themselves to the interconnected channels generating modular sheets with patterned cells.

[0018] In various embodiments, the hydrogel composition can be a hydrogel sheet. In various embodiments, the hydrogel composition can be configured to be in a shape of a graft or an implant.4916-7926-95402 Page 3 of 47 065472-001029WOPT

[0019] In various embodiments, the hydrogel composition can comprise pure GelMA, or GelMA and PGDA. In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising GelMA (5-10% w / v). In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising PEGDA (1-4% w / v) and GelMA (5-10% w / v). In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising PEGDA (3.5-6.5% w / v) and GelMA(7.5% w / v).

[0020] In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising GelMA (7.5% w / v, G7.5). In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising PEGDA (2.5% w / v, P2.5) and GelMA (7.5% w / v, G7.5). In various embodiments, the hydrogel composition can be fabricated from a photoresin comprising PEGDA (5.0% w / v, P5.0) and GelMA (7.5% w / v, G7.5).

[0021] In various embodiments, the hydrogel composition can be made by a method comprising: designing microsquares on a sheet having 100-600 pm spacings to create microchannels having 100-600 pm dimensions; pouring a photoresin into the microchannels and keeping the sheet at about 2-10°C allow for physical gelation, wherein the photoresin can comprise pure GelMA or wherein the photoresin can comprise GelMA and PGDA; exposing the microchannels to about 390-420 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet; melting the photoresin in the embedded hydrogel sheet at about 30-42°C for about 5-15 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

[0022] In various embodiments, the hydrogel composition can be made by a method comprising: designing microsquares on a sheet having 200-400 pm spacings to create microchannels having 200-400 pm dimensions; pouring a photoresin into the microchannels and keeping the sheet at about 4°C allow for physical gelation, wherein the photoresin can comprise pure GelMA or wherein the photoresin can comprise GelMA and PGDA; exposing the microchannels to about 405 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet; melting the photoresin in the embedded hydrogel sheet at about 37°C for about 10 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

[0023] In various embodiments, the micromodules can be microgels in a size range of about 100 pm to 900 pm. In various embodiments, the micromodules can be microgels in a size4916-7926-95402 Page 4 of 47 065472-001029WOPTrange of about 100 gm to 600 gm. In various embodiments, the micromodules can be microgels in a size range of about 200 gm to 400 gm.

[0024] In various embodiments, the micromodules can be microgel that are rod-shaped, cube-shaped, cuboid-shaped, ellipsoid-shaped, triangle-shaped, star shaped, or combinations thereof.

[0025] In various embodiments, the cells of the second cell type can be islet cells, mesenchymal stem cells (MSCs), smooth muscle cells, or pericytes.

[0026] Various embodiments provide for a composition comprising cells of the first cell type embedded in a modular composition with patterned cells produced by any one of the methods of the invention described herein.

[0027] In various embodiments, the cells of the first cell type are endothelial cells derived from induced pluripotent stem cells (iECs). In various embodiments, the iECs are in the interconnected channels of the modular composition with patterned cells.

[0028] In various embodiments, further comprising cells of the second cell type embedded in a modular composition with patterned cells produced by any one of the methods of the invention described herein.

[0029] In various embodiments, the cells of the second cell type are in the micromodules of the modular composition with patterned cells.

[0030] In various embodiments, the modular composition with patterned cells is a patch. In various embodiments, the patch comprises: islet cells in the micromodules of the modular composition with patterned cells and iECs in the interconnected channels of the modular composition with patterned cells.

[0031] In various embodiments, the modular composition with patterned cells is a vascular graft. In various embodiments, the vascular graft comprises iECs in interconnected channels of the modular composition with patterned cells.

[0032] In various embodiments, the modular composition with patterned cells is a wound dressing. In various embodiments, the wound dressing comprises iECs in the interconnected channels of the modular composition with patterned cells and MSCs in the micromodules of the modular composition with patterned cells.

[0033] Various embodiments provide for a method of treating a disease or condition, comprising: administering the modular composition with patterned cells of any one of claims 33-43 to a subject afflicted with the disease or condition.

[0034] In various embodiments, the disease or condition is critical limb threatening ischemia, peripheral artery disease, diabetic retinopathy, pulmonary hypertension, Ischemic4916-7926-95402 Page 5 of 47 065472-001029WOPTheart disease, chronic wound, bum, stroke, osteonecrosis (avascular necrosis), bone fracture, or non-union bone fracture.

[0035] In various embodiments, the cells of the first cell type are iECs.

[0036] In various embodiments, the condition is a wound and the cells of the first cell type are iECs. In various embodiments, the condition is a bum wound and the cells of the first cell type are iECs. In various embodiments, the disease or condition is diabetes and the cells of the first cell type are iECs and the cells of the second cell type are islet cells.

[0037] In various embodiments, the cells of the second cell type are smooth muscle cells.

[0038] Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various features of embodiments of the invention.BRIEF DESCRIPTION OF THE FIGURES

[0039] Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

[0040] Figure 1 (panels A-D) shows FLight-based fabrication of microgels. (A) Different microgel shapes were fabricated using different hydrogel compositions, (i) GelMA 7.5%, (ii) PEGDA2.5% / GelMA 7.5%, (iii) PEGDA 5% / GelMA7.5%. (B) Frequency sweep analysis of different hydrogel compositions demonstrating different storage moduli. (C) Stiffness of different hydrogel compositions. (D) Injectability of fabricated microgels through a 21G needle. Scale bars: 500 pm, ****p<0.0001.

[0041] Figure 2 (panels A-D) shows biofabricated microgels can impact cellular organization by controlling OMI. (A) Schematic representation demonstrating how OMI can be modulated to control cellular arrangement in microgels of different shape by controlling internal architecture. (B) Live-dead staining showed high cellular viability of HDF cells over 5 days with (i) microrods providing an elongated cellular arrangement due to their fibrillar architectures inside the microgels, whereas (ii) cells organized randomly in square shaped microgels. (C) Presto blue assay demonstrating cellular growth in both shapes over 7 days. (D) High-magnification staining for cytoskeleton (Phalloidin staining) demonstrating how internal structures can impact cellular arrangement in microgels. Scale bars'. 200 pm, ****p<0.0001.

[0042] Figure 3 (panels A-F) shows fibrillated rods can provide guided cellular growth. (A) Schematic illustration demonstrating the possible application of fibrillated4916-7926-95402 Page 6 of 47 065472-001029WOPTmicrogels for cell-based therapeutics, wherein microgels can help in a cellular organization that can be utilized as fillers for treatment of muscle loss. (B) Metabolic activity of C2C12 cells encapsulated in microgels before and post-injection. No significant difference was observed in metabolic activity post-injection. (C) Live / dead staining demonstrating high cellular viability and cell alignment during 5 days of culture, (i) Before injection, (ii) After injection. No impact on cellular viability nor cellular alignment was observed post-injection. (D) Phalloidin / DAPI staining showing the alignment of the cytoskeleton on microgels, (i) Before injection, (ii) After injection. No impact on cellular alignment was observed post-injection (Scale bar: 200 pm). (E) Microgels stained positive for Myosin after 7 days of culture in differentiation media (Scale bar: 100 pm). Prior to switching to differentiation media, the microgels were cultured in growth media for 7 days, followed by an additional 7 days of induction. While cells in 2D cultures exhibited some capacity for differentiation, their effectiveness was notably inferior compared to the 3D culture in FLight microgels (Scale bar: 200 pm). (F) Quantitative assessments of myotube length and thickness. ****p<0.0001.

[0043] Figure 4 (panels A-C) shows Janus-type modular assembly mimicking physiology of retina. (A) Schematic representation showing fabrication of Janus-type units with the capacity to control cellular arrangements. Epithelial monolayer (RPEs) surrounding pillar of Janus Assembly loaded with photoreceptors (PRs) can mimic the physiology of cellular arrangement in the retina. (B) Microscopic observation of Janus Type assembly showing fibrillated pillars biofabricated on GelMA membranes. (C) Cell loaded Janus type assembly, (i) Tracked cells loaded in two regions of Janus type assembly (Scale bar: 200 pm), (ii-iii) IF staining demonstrating cells positive for ZO-1 (Red: ZO-1, Blue: Nuclei, Green: Phalloidin; Scale bars: 100 pm) and recoverin (Red: Recoverin, Blue: Nuclei, Scale bars: 200 pm) respectively in base and pillars of Janus Assembly.

[0044] Figure 5 (panels A-D) shows anisotropic MAPs can be fabricated using non-spherical microgels. (A) (i-iii) MAP composed of rods and squares showing different internal architecture, micro-porous architecture, and different stiffness; (iv) Schematic representation demonstrating cells infiltrating MAPs. (B) HDF cells cultured on MAPs over 5 days, (i) MAP rods, (ii) MAP squares. Cell proliferated over 5 days in both MAPs and infiltrated the micropores (white arrows). Red: Microgels, Green: FITC tracked cells. Scale bars: 200 pm. (C) (i) 3D image of rod-shaped MAP and respective cell infiltration; (ii) 3D image of square-shaped MAP and respective cell infiltration; (D) Comparison of cell infiltration within both MAPs. Scale bars'. 200 pm. *p<0.05, ****p<0.0001.4916-7926-95402 Page 7 of 47 065472-001029WOPT

[0045] Figure 6 (panels A-F) shows subcutaneous implantation of microgels in a mouse model. Both microgels (rods and squares) were loaded with QK (angiogenic peptide) to evaluate their angiogenic potential and neo-tissue formation. (A) Schematic representation demonstrating the process. 200 pl of each shape were administered using a 21G needle. (B) H & E staining demonstrating tissue infiltration through micro-pores of injected microgel plug post 14 days of implantation, (i) Microrods without QK peptide, (ii) Microrods with QK peptide, (iii) Microsquares without QK peptide, (iv) Microsquares with QK peptide. Scale bars: 500 pm. (C) Quantified tissue infiltration. (D) Neo-vascularization at the implantation site, i) Microrods without QK peptide, (ii) Microrods with QK peptide, (iii) Microsquares without QK peptide, (iv) Microsquares with QK peptide. Peptide loading enhanced the process of new vessel formation. Arrows represent newly formed vessels stained positive for CD31. Scale bars :100 pm. (E) Quantified vessels. (F) Quantified CD31+cells. E: Epidermis, D: Dermis, SC: Subcutaneous cavity. *p<0.05, **p<0.01***p<0.0002, ****p<0.0001.

[0046] Figure 7 (panels A-C) shows injectability evaluation of fabricated microgels. (A) A syringe loaded with microgels (rods). (B) Microrods passing effortlessly through a 20G channel (microrods were tagged with Rhodamine to enable easy visualization); (C) Microrods can maintain their structure post-injection. Inserts showing microscopic images post injection with retention of fibrillation post injection. Scale bars: 500 pm.

[0047] Figure 8 (panels A-B) shows controlling OMI for altering fibrillation in microgels of different shapes. (A) Phase contrast bright field images depicting fibrillated vs. non fibrillated nature of anisotropic microgels with different shapes, (i) Rods showing fibrillated architecture depicted by arrows, (ii) Absence of fibrillation in microgels by tuning OMI. (B) Confocal images depicting (i) microrods showed the presence of microfilaments whereas (ii) geometries like square showed absence of microfilaments. Insets represent high-magnification images of individual microgels. Rhodamine-conjugated GelMA was used for microgel fabrication for their visualization under a confocal microscope. Scale bars: 500 pm.

[0048] Figure 9 shows modulating fibrillation within microgels by controlling OMI. (i) No fibrillation observed in geometries with lower aspect ratio, (ii) Fibrillation phenomenon depicted in bright field images (top view) showing dotted architecture due to presence of filaments in geometries with higher aspect ratio. Scale bars: 500 pm.

[0049] Figure 10 (panels A-C) shows microfibrillation in microgels (rods) fabricated using different concentration of pre-polymers. (A) BF confocal z attack images were captured and observed in 2.5D mode to see the internal arrangement of microfilaments in microgels composed of different pre-polymer compositions (G7.5, P2.5G7.5, P5G7.5). Microfilaments4916-7926-95402 Page 8 of 47 065472-001029WOPTshowed microchannels in between them. (B) Quantified diameter of microfilaments among microgels fabricated using different pre-polymer compositions. (C) Quantified diameter of microchannels among microgels fabricated using different pre-polymer compositions

[0050] Figure 11 shows FLight microgels can control cellular arrangement by controlling internal and external microgel architecture. Scale bars: 200 pm

[0051] Figure 12 (panels A-C) shows external microgel architecture does not define cellular response. Performance of rod shape microparticles fabricated with and without FLight. (A) Live / dead staining showing growth of viable Human Dermal Fibroblasts (HDFs) in microgels fabricated using FLight (with internal fibrillation) and no FLight (no internal fibrillation). Cell elongation and fusion can be observed in FLight microgels whereas cells tend to grow randomly in rods fabricated with no FLight. Scale bars: 200 pm. (B) Cytoskeleton arrangement of cells in microgels fabricated with and without FLight. Scale bars: 200 pm. (C) Quantified elongation length in two microunits at different time points. ****p<0.0001.

[0052] Figure 13 (panels A-B) shows phalloidin / DAPI stained microgels for visualization of cellular arrangement in two types of microgels. (A) Rods with aligned orientation of cells, and (B) Squares with random orientation of cells. Scale bars: 200 urn.

[0053] Figure 14 (panels A-B) shows low magnification images of Live / Dead-stained microrods loaded with C2C12 cells. (A) before and (B) post injection over 5 days, demonstrating no impact of injection on cellular viability. Scale bars: 500 urn.

[0054] Figure 15 (panels A-B) shows phalloidin / DAPI stained microrods loaded with C2C12 cells. (A) before and (B) post injection over 5 days, demonstrating no impact of injection on cellular alignment. Scale bars: 200 am.

[0055] Figure 16 shows rods stained positive for early myogenesis marker Desmin on day 4 post differentiation. Low magnification images showing high number of cells stained positive for Desmin. Scale bars: 200 pm. High magnification images showing aligning of muscle cells along length of rods stained positive for Desmin. Scale bars: 50 pm.

[0056] Figure 17 shows low magnification image demonstrating high expression for Myosin Heavy Chain protein in FLight microgels. Scale bars: 200 pm.

[0057] Figure 18 shows the formation of a viable RPE monolayer on GelMA membranes was assessed using a live / dead assay. The images illustrate that by day 14, the RPEs had adopted a cobblestone morphology.

[0058] Figure 19 shows Live / Dead images of photoreceptors (PRs) aligning on pillar. High cell viability was observed over 7 days of culture, (i) Day 3, (ii) Day 5, and (iii) Day 7. Pillar was detached from the base for observation. Scale bars: 200 m.4916-7926-95402 Page 9 of 47 065472-001029WOPT

[0059] Figure 20 (panels A-C) shows microgels (squares) stitched into hydrogel sheets through an array of projections can create modular sheets with interconnected channels. (A) Schematic representation demonstrating how such modular scaffolds can be utilized to fabricate hydrogel sheets with patterned vascularization. (B) Gross appearance of microgel sheets (Scale bar: 5 mm) and microscopic image showing presence of interconnected channels (Scale bars: 500 pm), (C) Modular hydrogel sheets seeded with iPSC-derived endothelial cells stained for live / dead and CD31 (PECAM-1, Platelet endothelial cell adhesion molecule-1) at time points demonstrating seeded endothelial cells can restrict themselves to channels generating modular sheets with patterned cells, (i) Live / Dead staining on Days 3 and 7, (ii) CD31 / DAPI staining on Days 3 and 7. Scale bars: 200 pm.

[0060] Figure 21 shows frequency sweep analysis of MAP composed of rods and squares.

[0061] Figure 22 (panels A-B) shows rendered z stacks showing cell infiltration in MAPs composed of rods and squares over 5 days. (A) Infiltration of cells seeded on MAPs composed of rods at (i) Day 1, (ii) Day 3, and (iii) Day 5, respectively; (B) Infiltration of cells seeded on MAPs composed of squares at (i) Day 1, (ii) Day 3, and (iii) Day 5, respectively.

[0062] Figure 23 shows degree of functionalization of two different random batches of GelMA calculated using Ninhydrin assay. Degree of functionalization (DoF) was consistent among batches.

[0063] Figure 24 (panels A-B) shows an exemplary scheme for FLight-based fabrication of microgels with fibrillar architecture. (A) Bioink composed of varying concentrations of GelMA / PEGDA as a precursor can be used to fabricate microgels. (B) The customized DMD setup can selectively fabricate microgels of different shapes with or without fibrillar architecture based on optical modulation instability (OMI). (C) Fibrillation of microgels can control cellular arrangement in 3D.

[0064] Figure 25 shows an exemplary fabrication: Light based 3D fabrication

[0065] Figure 26 shows an exemplary wound dressing with co-cultured cells (MSCs / iECs) for use in bum wound healing. Wound patch for stem cell delivery. iECs co-cultured can help in faster anastomosis and support longevity in survival of Stem Cells.

[0066] Figure 27 shows an exemplary patch for islet delivery. Co-culture models have known to support survival of islets in previous studies due to quicker anastomosis. Utilize such patches for islets delivery.

[0067] Figure 28 (panels A-B) shows an exemplary vascular graft.4916-7926-95402 Page 10 of 47 065472-001029WOPTDESCRIPTION OF THE INVENTION

[0068] All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton el al., Dictionary of Microbiology and Molecular Biology 3rded, Revised, J. Wiley & Sons (New York, NY 2006); March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 7thed., J. Wiley & Sons (New York, NY 2013); and Sambrook and Russel, Molecular Cloning: A Laboratory Manual 4thed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2012), provide one skilled in the art with a general guide to many of the terms used in the present application.

[0069] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

[0070] As used herein the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 5% of that referenced numeric indication, unless otherwise specifically provided for herein. In various embodiments, the term “about” when used in connection with a referenced numeric indication can mean the referenced numeric indication plus or minus up to 4%, 3%, 2%, 1%, 0.5%, or 0.25% of that referenced numeric indication, if specifically provided for in the claims.

[0071] The term “condition” when referring to a subject is understood in the present disclosure as status of subject that may be described by physical, mental or social criteria. It includes as well so-called “healthy” and “diseased” conditions, therefore it is not limited to the WHO definition of health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.” but includes disease and infirmity.

[0072] The term “disease” refers to an abnormal condition affecting the body of an organism. The term “disorder” refers to a functional abnormality or disturbance. The terms disease or disorder are used interchangeably herein unless otherwise noted or clear given the context in which the term is used.

[0073] A “healthy subject” or “normal subject” is a subject (e.g., patient) who does not have the disease or disorder that is being treated in the subject in need thereof.

[0074] As used herein, a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents4916-7926-95402 Page 11 of 47 065472-001029WOPTinclude mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, and canine species, e.g., dog, fox, wolf. The terms, “patient”, “individual” and “subject” are used interchangeably herein. In an embodiment, the subject is mammal. The mammal may be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. In addition, the methods described herein may be used to treat domesticated animals and / or pets. In some embodiments, the subject is a human.

[0075] “Rod-shaped” as used herein refers to having a ratio of length to width (i.e., L / W) of greater than 1.2. In various embodiments, the ratio of length to width is between 1.2-100.0. In various embodiments, the ratio of length to width is greater than 1.3. In various embodiments, the ratio of length to width is between 1.3-100.0. In various embodiments, the ratio of length to width is greater than 1.5. In various embodiments, the ratio of length to width is between 1.5-100.0. In various embodiments, the ratio of length to width is between 2-75, 2-50, 2-25, 2-10, or 2-5. In various embodiments, the ratio of length to width is between 1.2-1.5, 1.3-1.5, 1.5-10, 1.5-9, 1.5-8, 1.5-7, 1.5-6, 1.5-5, 1.5-4, 1.5-3, or 1.5-2. In various embodiments, the ratio of length to width is between 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10. In various embodiments, the ratio of length to width is between 2-15, 2-20, 2-30, or 2-40. In various embodiments, the ratio of length to width is between 3-5, 3-10, 3-15, 3-20, or 3-40. In various embodiments, the ratio of length to width is between 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, or 9-10.

[0076] Described herein, we overcome these challenges by utilizing Filamented Light (FLight) biofabrication, a novel technique that enables the precise organization of cellular alignment within the microgels.

[0077] Recently deep vat photopolymerization (DVP) 3D printing approaches have gained much attention in 3D biofabrication. DVP techniques such as volumetric bioprinting have allowed researchers to create complex millimeter scale tissue architectures within fraction of seconds with uncompromised cellular viability. Similarly, FLight biofabrication have been shown to generate millimeter scale anisotropic hydrogel constructs that can provide filamentous niches to control cellular arrangement. Although these techniques have gone a long way in resolving many issues associated with light based biofabrication techniques, they often are designed for macroscale constructs with their minimal utilization for fabricating microgels. Although some of recent researches have explored the potential of light based biofabrication at microscale, the technique was unable to generate microparticles with anisotropies.

[0078] Described herein is a FLight-based microfabrication technique for creating anisotropic microgels that can effectively influence cellular behavior. By tuning the OMI of4916-7926-95402 Page 12 of 47 065472-001029WOPTlight during its interaction with hydrogels, we demonstrated that we could modify the internal structure of these microgels. This innovative approach allows for the design of microgels with tailored internal architectures that can steer cellular organization in 3D space. Our research illustrates how this precise control over cellular behavior can address the complexities found in various tissues, including muscle and retinal tissues. The injectability of these microgels, combined with their ability to regulate cellular arrangement, positions them as promising tools for regenerative medicine applications. In essence, this microfabrication method paves the way for developing modular tissue engineering platforms. By enabling the production of anisotropic microgels, our approach holds significant potential for advancing regenerative therapies. These tailored microgels could lead to more effective treatments by providing an environment that closely mimics the native tissue architecture and functionality, ultimately enhancing tissue repair and regeneration. By tailoring the polymer compositions and minimizing light scattering for photo resins loaded with high cell density / organoids, the technique can be further employed to generate microgels with high cellular densities, further exploring its potential to develop complex micro-niches mimicking in vivo physiologies.

[0079] Microgels were fabricated using gelatin methacryloyl (GelMA, degree of methacrylation 75%) / polyethylene glycol diacrylate (PEGDA, Mn 750 Da) based photoactive resins wherein the fraction of two components was varied to prepare gels of different stiffnesses. We used a customized 2D projector system to focus collimated light beam of designed geometries using a digital micromirror device (DMD) onto a photoactive resin. The concept is based on the OMI of the uniform light beam as it passes through a non-linear medium, breaking it into microfilaments. This can result in macroscale constructs that are highly filamentous and can be utilized to control cellular arrangements in 3D. While not wishing to be bound by any particular theory, we believe that such behavior of light could be used in making internal fibrillation in microgels (Figure 24).

[0080] Initially, we demonstrated the ability of our approach to fabricate microgels of varying chemistries, shapes and sizes ranging from 300 pm to 900 pm with a range of photoresin formulations, as shown in Figure lA(i-iii). Different photoresins were utilized composed of GelMA (7.5% w / v, G7.5) or GelMA blended with varying concentrations of PEGDA (P2.5G7.5, P5G7.5, where numbers represent w / v concentration of each polymer). We demonstrated that these formulations have mechanical properties that ranged from 10-50 kPa (Figure 1 B, C), allowing us to target tissues of varying stiffnesses. Moreover, we confirmed that these microgels were injectable, envisioning their applications for minimally invasive therapeutics (Figure ID, Figure 7).4916-7926-95402 Page 13 of 47 065472-001029WOPT

[0081] We subsequently investigated the degree and pattern of fibrillation in microgels synthesized from various pre-polymer concentrations (Figures 8 and 9). Our observations revealed that microgels with a low aspect ratio (shapes such as square, star, triangle) lacked filamentous structures, while those with a high aspect ratio, such as rod-shaped microgels, exhibited an internal fibrillated architecture. This could be due to depth of penetration of light in photoresins, with deeper penetration enhancing the waveguiding effects (as observed in case of high aspect ratio microgels such as rods) whereas the phenomenon could be greatly suppressed when the penetration depth was lesser (as in case with flattened microgels such as squares, triangles, and any other 2D shapes). Cross-sectional analyses of the higher aspect ratio microgels revealed a dotted grid-like arrangement of filaments, with microchannels interspersed throughout. Conversely, the microgels with lower aspect ratios displayed a smooth architecture, indicating the absence of fibrillation (Figure 9). We also collected additional Z-stack images to analyze the filament arrangement within microgels of high aspect ratios fabricated using different pre-polymer compositions, to analyze the role of polymer composition in controlling fibrillation. All formulations displayed an internal filamentous architecture with interspersed microchannels. Notably, reducing the PEGDA concentration resulted in an increase in both the diameter of the filaments and the size of the corresponding microchannels (Figure 10).

[0082] Cellular arrangement is an important factor that can modulate tissue functionality. We demonstrated the capability of our biofabricated microgels to influence cellular alignment (Figure 2A and Figure 11). While not wishing to be bound by any particular theory, we believe that the internal fibrillation in elongated geometries, such as rods, offers directional cues for cell alignment, while the absence of fibrillation in low aspect ratio geometries, like square modules, leads to random organization of cells. We fabricated microgels encapsulating human dermal fibroblasts (HDFs) with varying aspect ratios — rods representing high aspect ratio geometries (~ 500 pm) and squares representing low aspect ratio geometries (~ 500 pm) — to assess cellular arrangement over time. Live / dead staining results (Figure 2B) showed that cells remained viable within both rod and square microgels. However, the organization of the cells differed between the two microgel types. Cells within rod-shaped microgels exhibited alignment over five days (Figure 2B-i), while those in square-shaped microgels maintained a random orientation (Figure 2B-ii). The Alamar Blue assay conducted over five days indicated a significant increase in metabolic activity (****p<0.0001) (Figure 2C), confirming the absence of toxicity from the bioink formulation and light exposure during fabrication. Importantly, the observed cellular alignment was attributed solely to internal4916-7926-95402 Page 14 of 47 065472-001029WOPTfibrillation, rather than the external architecture of the microgels (Figure 12). High-resolution confocal imaging of the cytoskeleton further illustrated the ability of our fabricated micro-units to regulate cellular arrangement at the microscale (Figure 2D and Figure 13). Thus, our findings provide support that the newly developed microgel system is not only anisotropic in shape but also features an internal architecture that can be tailored to modulate cellular arrangements in various configurations.

[0083] Next, we tested the utility of FLight-based microgels in fabricating anisotropic tissues like muscle. Although microgels have been researched recently as injectable cellcarriers for treatment of volumetric muscle loss, the isotropic nature of such systems restricts their potential for efficient cell-based therapies. Given that our FLight microgels with fibrillation can provide directional cues, we envisioned their use as cell-laden injectable microfillers in regenerative medicine (Figure 3A). We fabricated rod-shaped microgels approximately 300 pm in diameter and assessed their potential to align muscle cells. As demonstrated (Figure 3B), there was no observed impact on cell metabolic activity following injection. Cells demonstrated an increase in metabolic activity over 7 days (****p<0.0001), with no significant differences noted before and after injection. Live / dead staining confirmed that cells remained viable and aligned throughout 5 days of culture (Figure 3C-i-ii and Figure 14), with no visible effects of injection on cell viability or organization. Cytoskeleton staining (Figure 3D-i-ii and Figurel4) indicated that cells began to align by day 1 and populated the microgels over 5 days, with fused cytoskeleton structures observed at day 5. We did not detect any adverse effects of injection on the arrangement of the cytoskeleton (Figure 3D-i-ii and Figure 15).

[0084] Moreover, the advantages of FLight microgels were highlighted by their ability to support muscle maturation. Following cell fusion observed in cytoskeleton staining, cells were cultured for another 7 days in induction media, to induce muscle formation and maturation. To confirm the commitment of cells towards myogenesis, Desmin staining was conducted, specifically 4 days post-induction in differentiation media (early time point). The results revealed a significant number of cells that tested positive for Desmin, indicating their differentiation towards the muscle lineage (Figure 16). By day 7 following induction, FLight microgels exhibited remarkable effectiveness in promoting cell differentiation, leading to the development of highly aligned myotubes within the microgel (Figure 3E and 17). In contrast, cultures maintained in two-dimensional (2D) environments showed significantly less successful differentiation, largely due to their inability to facilitate directional growth of the cells.4916-7926-95402 Page 15 of 47 065472-001029WOPT

[0085] Further quantitative analysis of myotube parameters — such as their length and width, as depicted in Figure 3F — reinforced the superior capability of FLight microgels in fostering positive cellular responses. These findings underscore the importance of the three-dimensional architecture provided by the microgels, which effectively mimics the natural extracellular environment. This environment is essential for supporting the complex interactions and alignment that drive optimal muscle cell development, ultimately enhancing the functionality and maturity of the engineered muscle tissue.

[0086] To assess the effectiveness of FLight-based biofabrication in replicating the intricate cellular structures typically found in tissues such as the retina, we fabricated Janus-type assembly (Figure 4A), wherein photoreceptors (PRs) loaded fibrillated microrods were biofabricated on top of GelMA membranes that contained a confluent monolayer of retinal pigment epithelial (RPE) cells. These assemblies can replicate the retinal structure, with such cellular arrangements being crucial for ensuring proper functionality. Microscopic analysis of the Janus-type assembly (Figure 4B) reveals filamentous microrods biofabricated atop GelMA membranes. To delineate distinct cell-laden regions within the Janus-type assembly, cells were labeled with green and red fluorescence trackers (Figure 4C-i). Initially, RPE-seeded GelMA membranes were observed for 14 days to verify the formation of a viable monolayer of RPEs (Figure 18). Subsequently, the RPEs were cultured for an additional 7 days to promote the maturation of the established monolayer. Following this maturation period, photoreceptor-loaded fibrillated rods were biofabricated on top of the GelMA membranes containing the matured RPE monolayer. Observation of the microrods indicated that PRs could align and sustain high viability over a 7-day culture period (Figure 19). Immunofluorescence staining on day 7 further demonstrated that encapsulated PRs retained expression of Recoverin, a phototransduction-related protein (Figure 4C-ii). Additionally, base-level microscopic analysis revealed a monolayer of RPEs with tight junction formation, as evidenced by immunofluorescence staining for ZO-1 (Figure 4C-iii). These Janus-type microtissue constructs have potential applications in tissue engineering and regenerative medicine. Specifically, the fabricated retina-mimicking assembly could be employed in the treatment of age-related macular degeneration, with PR-loaded assemblies and supportive RPEs potentially serving as implantable microtissues.

[0087] We further explored the adaptability of our fabrication system by configuring these modules into various setups to recreate microtissue-like assemblies. In the body, tissues typically possess a well-organized vascular pattern essential for their function and development. While many studies have shown that co-culture models can accelerate the4916-7926-95402 Page 16 of 47 065472-001029WOPTanastomosis process, most have struggled to control or pattern these cellular arrangements effectively. Moreover, these studies did not consider that tissues are a collation of micromodules connected through a well -organized vasculature. To illustrate this, we created a modular microgel sheet featuring an array of microsquares interconnected by perfusable microchannels. As demonstrated (Figure 20A), while not wishing to be bound by any particular theory, we believe that these microchannel-embedded sheets could be used to culture human donor-derived endothelial cells selectively within the channels. This would result in scaffolds with patterned, well -organized vascular networks around the micromodules, suitable for housing tissue-specific cells. Figure 20B-i-ii presents both the macroscopic and microscopic views of the micro-modular assembly, highlighting the connection of microsquares and the presence of micro-channels. We investigated the potential of these micro-modular units for creating patterned cellular arrangements. Endothelial cells derived from induced pluripotent stem cells (iECs) seeded onto the micro-modular scaffolds, as shown in Figure 20C-i-ii, demonstrated their ability to confine themselves to the channels. By day 7, these cells formed a well-defined patterned architecture with high viability and significant expression of the canonical vascular endothelial cell marker CD31 / PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1). These micro-modular hydrogel sheets effectively replicate the arrangement of micro-units connected by vasculature, akin to the structure found in native tissues.

[0088] Next, we assessed the capacity of microgels to support host tissue growth and vascularization when employed as injectable materials. To demonstrate this, we utilized microgel assemblies, referred to as microporous scaffolds (MAPs), which exhibited distinct in vitro and in vivo cellular infiltration patterns that were influenced by the geometry of the microgels. In vitro, we annealed square- and rod-shaped microgels into MAPs and evaluated the impact of microgel shape on cellular infiltration. While MAPs made from square and rod shaped microgels exhibited similar overall porosity, their internal 2D architecture differed, with square-based MAPs displaying a higher degree of pore interconnectivity compared to rodbased MAPs (Figure 5A-i-ii). Mechanical property analysis revealed significant differences in storage modulus (G’) between the two MAP types (*p<0.05) (Figure 5A-iii and Figure 21).This variation in pore structure and mechanical stiffness influences cellular infiltration. To test this hypothesis, human dermal fibroblasts (HDFs) were cultured on the MAPs and cell growth and infiltration was monitored for 5 days. Cell confluence increased on both MAP types from day 1 to day 5, with cells infiltrating the pores (Figure 5B-i-ii). Volumetric Z-stack images confirmed that cells began infiltrating both MAPs from day 1, with peak infiltration observed4916-7926-95402 Page 17 of 47 065472-001029WOPTby day 5 (Figure 22). However, the depth of infiltration was shape-dependent, with significantly greater infiltration occurring in square-based MAPs compared to rod-based ones (****p<0.0001) (Figure 5C-D). Overall, we demonstrated that regardless of the particle shape, both types of assemblies enabled efficient cell growth and infiltration, owing to their porous architecture. These findings are crucial for understanding the ability of such injectable assemblies to support cellular infiltration, highlighting their advantage over traditional bulk hydrogels.

[0089] Further we conducted subcutaneous implantation of square- and rod-shaped microgel plugs in a mouse model. To enhance the therapeutic potential of the microgels, they were loaded with QK peptide, an angiogenic factor known to promote angiogenesis. The study involved four experimental groups (Figure 6A): Rods and Squares, each with and without QK peptide (200 pl of each microgel plug), where QK- represents microgels without peptide and QK+ denotes those loaded with the angiogenic peptide (500 pg / ml of microgel). Histological analysis at 14 days post-injection revealed that both microgel plugs facilitated cellular infiltration and neo-vascularization at the implantation site due to their microporous architecture (Figure 6B-i-iv). Notably, peptide-loaded microgels exhibited a more pronounced effects, with square-shaped microgels showing a significantly greater degree of infiltration and neo-vessel formation compared to rod-shaped microgels (**p<0.01) (Figure 6B-C). This finding aligns with our in vitro results, suggesting that microgels allowed cellular infiltration because of interconnected pore network. Also, the results can infer the importance of pore interconnectivity in governing the phenomenon of cellular migration, giving our technique an edge to fabricate microgels of unique shapes and sizes. While the internal architectures can well control the arrangement of the loaded cells, external structures can provide a diverse range of porosities, thus allowing us to control cellular response to greater extent.

[0090] Immunofluorescence staining for CD31, a marker for endothelial cells, was performed to assess new vessel formation. The CD31-stained tissue sections (Figure 6D-i-iv) indicated that peptide-loaded microgels stimulated greater vessel formation compared to nonpeptide-loaded microgels, with squares showing superior vascularization compared to rods. This underscores the significant role of microgel shape in promoting neo-tissue growth and vascularization. Quantitative analysis of new vessel formation and CD31+cell counts further supported these observations, showing significantly enhanced neo-vascularization in peptide-loaded microgels (Figure 6E and F; *p<0.05) and notably more in square-shaped microgels compared to rod-shaped ones (Figure 6E and F; ***p<0.0002 for neo-vessels and ****p<0.0001 for CD31+ cells).4916-7926-95402 Page 18 of 47 065472-001029WOPT

[0091] Overall, our study demonstrates that microgels can effectively support tissue regeneration and neo-vascularization, with microgel shape playing a crucial role in their performance. By modifying the shape of microgels, the scaffold's ability to promote tissue growth and vascularization can be optimized, allowing for tailored responses depending on the specific tissue and extent of new tissue formation required.

[0092] Various embodiments of the invention are based, at least in part, on these findings.

[0093] Various embodiments of the invention provide for a method of producing a modular composition with patterned cells, comprising:providing a hydrogel composition having aligned fibrillar structures, interconnected channels and modular scaffolds;seeding cells of a first cell type onto the modular scaffolds of the hydrogel composition; adding additional cell culture medium to the hydrogel composition; andculturing the cells of the first cell type in the hydrogel composition to generate the modular composition with patterned cells.

[0094] Various embodiments provide for a method of producing a modular composition with patterned cells, comprising:

[0095] providing a hydrogel composition having aligned fibrillar structures, interconnected channels and modular scaffolds;

[0096] seeding cells of a first cell type, wherein the cells of the first cell type are iPSC, endothelial cells derived from induced pluripotent stem cells (iECs), islet cells, smooth muscle cells, or pericytes, onto the modular scaffolds of the hydrogel composition;

[0097] adding additional cell culture medium to the hydrogel composition; and

[0098] culturing the cells of the first cell type in the hydrogel composition to generate the modular composition with patterned cells.

[0099] In various embodiments, the hydrogel composition further comprises cells of a second cell type embedded in micromodules in the hydrogel composition.

[0100] In various embodiments, the method further comprises seeding cells of a second cell type in micromodules in the hydrogel composition.

[0101] In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 10,000-1,000,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 25,000-500,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the4916-7926-95402 Page 19 of 47 065472-001029WOPTfirst cell type at a density of about 50,000-75,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 50,000-100,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 50,000-150,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 75,000-100,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 75,000-125,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 100,000-200,000 cells per 10 ml cell culture medium. In various embodiments, seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 100,000 cells per 10 ml cell culture medium.

[0102] In various embodiments, the cell culture medium is differentiation medium.

[0103] In various embodiments, the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 10-120 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 15-60 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 15-45 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 20-40 minutes incubation time after seeding the cells of the first cell type. In various embodiments, the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 30 minutes incubation time after seeding the cells of the first cell type.

[0104] In various embodiments, the additional cell culture medium is differentiation medium.

[0105] In various embodiments, seeding cells of the first cell type onto the hydrogel composition comprises adding endothelial cells derived from induced pluripotent stem cells (iECs) to the hydrogel composition a drop-wise manner at a density of about 100,000 cells per 10 ml in iEC differentiation medium; adding additional cell culture medium to the hydrogel4916-7926-95402 Page 20 of 47 065472-001029WOPTcomposition comprises adding additional iEC differentiation medium after about 30 minutes; and the the hydrogel composition is a hydrogel sheet comprising interconnected channels.

[0106] In various embodiments, the cells of the first cell type are iPSC, iECs, islet cells, smooth muscle cells, or pericytes. In various embodiments, the cells of the first cell type are iECs.

[0107] In various embodiments, the interconnected channels have 50-800 pm dimensions. In various embodiments, the interconnected channels have 100-600 pm dimensions. In various embodiments, the interconnected channels have 100-400 pm dimensions. In various embodiments, the interconnected channels have 200-400 pm dimensions. In various embodiments, the interconnected channels have 250-350 pm dimensions. In various embodiments, the interconnected channels have about 150 pm , about 200 pm , about 250 pm , about 300 pm , about 350 pm or about 400 pm dimensions.

[0108] In various embodiments, the cells of the first cell type grow in the interconnected channels. In various embodiments, the cells of the first cell type restrict themselves to the interconnected channels generating modular sheets with patterned cells.

[0109] In various embodiments, the hydrogel composition is a hydrogel sheet. In various embodiments, the hydrogel composition is configured to be in a shape of a graft or an implant.

[0110] In various embodiments, the hydrogel composition comprises pure GelMA. In various embodiments, the hydrogel composition is fabricated from a photoresin comprising GelMA (5-10% w / v). In various embodiments, wherein the hydrogel composition is fabricated from a photoresin comprising GelMA (7.5% w / v, G7.5).[oni] In various embodiments, the hydrogel composition comprises GelMA and PGDA. In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (1-4% w / v) and GelMA (5-10% w / v). In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (2-3% w / v) and GelMA (6-9% w / v). In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (3.5-6.5% w / v) and GelMA (7-8% w / v). In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (3.5-6.5% w / v) and GelMA (7.5% w / v). In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (2.5% w / v, P2.5) and GelMA (7.5% w / v, G7.5). In various embodiments, the hydrogel composition is fabricated from a photoresin comprising PEGDA (5.0% w / v, P5.0) and GelMA(7.5% w / v, G7.5).4916-7926-95402 Page 21 of 47 065472-001029WOPT

[0112] In various embodiments, the hydrogel composition is made by a method comprising:designing microsquares on a sheet having 100-600 pm spacings to create microchannels having 100-600 pm dimensions;pouring a photoresin into the microchannels and keeping the sheet at about 2-10°C allow for physical gelation,wherein the photoresin comprises pure GelMA or wherein the photoresin comprises GelMA and PGDA;exposing the microchannels to about 390-420 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet;melting the photoresin in the embedded hydrogel sheet at about 30-42°C for about 5-15 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

[0113] In various embodiments, the hydrogel composition is made by a method comprising:designing microsquares on a sheet having 150-500 pm spacings to create microchannels having 150-500 pm dimensions;pouring a photoresin into the microchannels and keeping the sheet at about 3-9°C allow for physical gelation,wherein the photoresin comprises pure GelMA or wherein the photoresin comprises GelMA and PGDA;exposing the microchannels to about 395-415 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet;melting the photoresin in the embedded hydrogel sheet at about 30-42°C for about 8-12 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

[0114] In various embodiments, the hydrogel composition is made by a method comprising:designing microsquares on a sheet having 200-400 pm spacings to create microchannels having 200-400 pm dimensions;pouring a photoresin into the microchannels and keeping the sheet at about 4°C allow for physical gelation,wherein the photoresin comprises pure GelMA or wherein the photoresin comprises GelMA and PGDA;4916-7926-95402 Page 22 of 47 065472-001029WOPTexposing the microchannels to about 405 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet;melting the photoresin in the embedded hydrogel sheet at about 37°C for about 10 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

[0115] In various embodiments, the micromodules are microgels in a size range of about 100 pm to 900 pm. In various embodiments, the micromodules are microgels in a size range of about 100 pm to 600 pm. In various embodiments, the micromodules are microgels in a size range of about 100 pm to 500 pm. In various embodiments, the micromodules are microgels in a size range of about 100 pm to 400 pm. In various embodiments, the micromodules are microgels in a size range of about 200 pm to 400 pm. In various embodiments, the micromodules are microgels in a size range of about 200 pm to 500 pm.

[0116] In various embodiments, the micromodules are microgels that are rod-shaped, cube-shaped, cuboid-shaped, ellipsoid-shaped, triangle-shaped, star shaped, or combinations thereof. In various embodiments, the micromodules are microgels that are rod-shaped, cubeshaped, or combinations thereof. In various embodiments, the micromodules are microgels that are rod-shaped. In various embodiments, the micromodules are microgels that are cube-shaped. In various embodiments, the micromodules are microgels that are cuboid-shaped, ellipsoidshaped or combinations thereof. In various embodiments, the micromodules are microgels that are cuboid-shaped. In various embodiments, the micromodules are microgels that are ellipsoidshaped.

[0117] In various embodiments, the cells of the second cell type are islet cells, mesenchymal stem cells (MSCs), smooth muscle cells, or pericytes.

[0118] Various embodiments provide for a composition comprising cells of the first cell type embedded in a modular composition with patterned cells produced by any one of the methods of the present invention described herein.

[0119] Various embodiments provide for a composition comprising cells of the first cell type, wherein the cells of the first cell type are iPSC, endothelial cells derived from induced pluripotent stem cells (iECs), islet cells, smooth muscle cells, or pericytes, embedded in a modular composition with patterned cells produced by any one of the methods of the present invention described herein.

[0120] In various embodiments, modular composition with patterned cells comprises cube-shaped microgels. In various embodiments, modular composition with patterned cells4916-7926-95402 Page 23 of 47 065472-001029WOPTcomprises cuboid-shaped microgels. In various embodiments, modular composition with patterned cells comprises rod-shaped microgels. In various embodiments, modular composition with patterned cells comprises ellipsoid-shaped microgels. In various embodiments, modular composition with patterned cells comprises cube-shaped and rod-shaped microgels. In various embodiments, modular composition with patterned cells comprises cuboid-shaped and ellipsoid-shaped microgels. In various embodiments, modular composition with patterned cells comprises microgels that are rod-shaped, cube-shaped, cuboid-shaped, ellipsoid-shaped, triangle-shaped, star shaped, or combinations thereof.

[0121] In various embodiments, the cells of the first cell type are endothelial cells derived from induced pluripotent stem cells (iECs). In various embodiments, the iECs are in the interconnected channels of the modular composition with patterned cells.

[0122] In various embodiments, the composition further comprises cells of the second cell type embedded in a modular composition with patterned cells produced by any one of the methods of the present invention described herein. In various embodiments, the cells of the second cell type are in the micromodules of the modular composition with patterned cells. In various embodiments, the cells of the second cell type are islet cells, mesenchymal stem cells (MSCs), smooth muscle cells, or pericytes.

[0123] In various embodiments, the modular composition with patterned cells is a patch. In various embodiments, the patch comprises: islet cells in the micromodules of the modular composition with patterned cells and iECs in the interconnected channels of the modular composition with patterned cells.

[0124] In various embodiments, the modular composition with patterned cells is a vascular graft. In various embodiments, the vascular graft comprises iECs in interconnected channels of the modular composition with patterned cells.

[0125] In various embodiments, the modular composition with patterned cells is a wound dressing. In various embodiments, the wound dressing comprises iECs in the interconnected channels of the modular composition with patterned cells and MSCs in the micromodules of the modular composition with patterned cells.

[0126] Various embodiments provide for a method of treating a disease or condition, comprising: administering any one of the modular composition with patterned cells of the present invention to a subject afflicted with the disease or condition.

[0127] In various embodiments, the disease or condition is ischemia, critical limb threatening ischemia, peripheral artery disease, diabetic retinopathy, pulmonary hypertension,4916-7926-95402 Page 24 of 47 065472-001029WOPTIschemic heart disease, chronic wound, bum, stroke, osteonecrosis (avascular necrosis), bone fracture, or non-union bone fracture.

[0128] In various embodiments, modular composition with patterned cells comprises cells of a first cell type. In various embodiments, the cells of the first cell type are iPSC, endothelial cells derived from induced pluripotent stem cells (iECs), islet cells, smooth muscle cells, or pericytes. In various embodiments, the cells of the first cell type are iECs.

[0129] In various embodiments, modular composition with patterned cells further comprises cells of a second cell type. In various embodiments, the cells of the second cell type are islet cells, mesenchymal stem cells (MSCs), smooth muscle cells, or pericytes.

[0130] In various embodiments, the condition is a wound and the cells of the first cell type are iECs. In various embodiments, the condition is a bum wound and the cells of the first cell type are iECs.

[0131] In various embodiments, the disease or condition is diabetes and the cells of the first cell type are iECs and the cells of the second cell type are islet cells.

[0132] In various embodiments, the disease or condition is ischemia and the cells of the first cell type are iECs.

[0133] In various embodiments, the cells of the second cell type are smooth muscle cells.

[0134] In various embodiments, the method treats patients with chronic wounds, diabetic ulcers, peripheral artery disease, ischemic tissue damage, or transplant-related vascular complications.

[0135] In various embodiments, the endothelial cells from induced pluripotent stem cells (iECs) are iECs as described in International Application No. PCT / US2023 / 083118, hereby incorporated by reference in its entirety as though fully set forth.

[0136] Briefly described herein are methods to generate the iECs that can be used in various embodiments of the present invention, as well as the iECs that can be used in various embodiments of the present invention

[0137] In various embodiments, the iECs are generated by a method comprising (i) differentiating induced pluripotent stem cells (iPSCs) into mesoderm cells by: removing cGMP feeder-free iPSC maintenance medium from plated induced pluripotent stem cells (iPSCs) and adding mesoderm induction medium, and culturing the iPSCs for about 1.5-2.5 days in about 36-38C and in the presence of about 4-6% CO2 to generate mesoderm cells;4916-7926-95402 Page 25 of 47 065472-001029WOPT(ii) differentiating the mesoderm cells into vascular progenitor cells by: removing the mesoderm induction medium and adding vascular progenitor medium, and culturing the cells for about 1.5-2.5 days in about 36-38C and in the presence of about 4-6% CO2 to generate vascular progenitor cells;(iii) differentiating the vascular progenitor cells into iECs by: dissociating the vascular progenitor cells by using a first dissociation enzyme for about 4-6 minutes at 36-38C and in the presence of about 4-6% CO2, wherein the dissociation enzyme comprises an animal origin free enzyme that cleaves peptide bonds on the C-terminal sides of lysine and arginine; neutralizing the vascular progenitor cells by using basal endothelial cell growth medium MV2 plus about 9-11% human AB serum, spinning the vascular progenitor cell solution, removing the basal endothelial medium, and resuspending the vascular progenitor cells in GMP-grade iEC differentiation medium, wherein the human AB serum comprises human serum lacking antibodies against A and B blood-type antigens that was converted from Pooled Plasma (Human), Solvent / Detergent Treated; plating the vascular progenitor cells at about 9,000-11,000 cells / cm2with iEC differentiation medium onto a dish that was previously coated with 4-6ug / ml human recombinant laminin 421 in PBS Mg+ / Ca+ for about 1.5-2.5 hours at about 36-38C and in the presence of about 4-6% CO2, culturing the vascular progenitor cells at about 36-38C and in the presence of about 4-6% CO2 for about 6-8 days, feeding about every other day with iEC differentiation medium to generate iECs;(iv) further culturing the iECs by: dissociating the iECs by using animal origin free enzyme that cleaves peptide bonds on the C-terminal sides of lysine and arginine (IX) for about 4-6 minutes at about 36-38C and in the presence of about 4-6% CO2; neutralizing the iECs using by using basal endothelial cell growth medium MV2 plus 9-11% Human AB serum, spinning the iEC solution, removing the basal endothelial medium, and resuspending the iECs in GMP-grade iEC differentiation medium, wherein the human AB serum comprises human serum lacking antibodies against A and B blood-type antigens that was converted from Pooled Plasma (Human), Solvent / Detergent Treated; plating the iECs at about 9,000-11,000 cells / cm2with iEC differentiation medium onto a dish that was previously coated with 5ug / ml human recombinant laminin 421 in PBS Mg+ / Ca+ for about 1.5-2.5 hours at about 36-38C and in the presence of about 4-6% CO2, culturing the iECs at about 36-38C and in the presence of about 4-6% CO2 for about 9-11 days, feeding about every other day with iEC medium, thereby generating iECs expressing CD31 and CD144.

[0138] In various embodiments, the method can further comprise dissociating the iECs that are generated in step (iv).4916-7926-95402 Page 26 of 47 065472-001029WOPT

[0139] In various embodiments, the method can further comprise providing plated iPSCs, wherein the plated iPSCs are made by: dissociating iPSCs with a cGMP enzyme-free human pluripotent stem cell selection and passaging reagent for 5 minutes and neutralizing the iPSCs with iPSC maintenance medium; triturating the iPSCs about 10-15 times to break large colonies of iPSCs to smaller colonies of iPSCs and to have a homogenous cell population that is about 60-200um diameter per iPSC colony; dissociating a subset of colony solution as single cells by using a dissociation solution, for 5 minutes at 37C water bath, wherein the dissociation solution comprises a cell detachment solution of proteolytic and collagenolytic enzymes and does not contain mammalian or bacterial derived products; neutralizing the dissociation solution by using a cGMP feeder-free iPSC maintenance medium, spinning the cell solution, removing the medium and resuspending the iPSCs in iPSC maintenance medium; removing laminin solution from a plating dish that previously coated with 5ug / ml human recombinant laminin 521 in PBS Mg+ / Ca+ for 2 hours in 37C and in the presence of 5% CO2; adding cGMP feeder-free iPSC maintenance medium to the plating dish; adding about 2000 iPSCs / cm2to the plating dish and culturing at 37C and in the presence of 5% CO2; changing the cGMP feeder-free iPSC maintenance medium daily for an additional 2 days.

[0140] In various embodiments, the mesoderm induction medium can comprise a final concentration of about 5-7uM CHIR99021 and about 1:900-1:1100 Antibiotic-Antimycotic (PSA) in iPSC differentiation medium, wherein the iPSC differentiation medium comprises a defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages. In various embodiments, the mesoderm induction medium can comprise a final concentration of about 5-7uM CHIR99021 in iPSC differentiation medium, wherein the iPSC differentiation medium comprises a defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages.

[0141] In various embodiments, the vascular progenitor medium can comprise final concentrations of about 20-30 ng / ml Bone Morphogenetic Protein 4 (BMP4), about 8-12 ng / ml FGF2, about 40-60 ng / ml VEGF165 and about 1:900-1:1100 Antibiotic-Antimycotic (PSA) in iPSC differentiation medium. In various embodiments, the vascular progenitor medium can comprise final concentrations of about 20-30 ng / ml Bone Morphogenetic Protein 4 (BMP4), about 8-12 ng / ml FGF2, and about 40-60 ng / ml VEGF165 in iPSC differentiation medium.

[0142] In various embodiments, the iEC differentiation medium can comprise Basal MV2, PSA, Human AB Serum (AB serum), Epidermal Growth Factor (EGF), Basic Fibroblast Growth Factor (FGF2), Long R3 Insulin-like Growth Factor (IGF-1), Vascular Endothelial Growth Factor 165 (VEGF 165), Ascorbic acid, and Hydrocortisone.4916-7926-95402 Page 27 of 47 065472-001029WOPT

[0143] In various embodiments, the iEC differentiation medium can comprise Basal MV2, 1:900-1:1100 PSA, 0.05-0.15 ml / ml Human AB Serum (AB serum), 4-6 ng / ml Epidermal Growth Factor (EGF), 8-12 ng / ml Basic Fibroblast Growth Factor (FGF2), 18-22 ng / ml Long R3 Insulin-like Growth Factor (IGF-1), 240-280 ng / ml Vascular Endothelial Growth Factor 165 (VEGF 165), 0.5-1.5 ug / ml Ascorbic acid, and 0.1-0.3 ug / ml Hydrocortisone.

[0144] In various embodiments, the method comprises(i) differentiating induced pluripotent stem cells (iPSCs) into mesoderm cells by: removing cGMP feeder-free iPSC maintenance medium from plated induced pluripotent stem cells (iPSCs) and adding mesoderm induction medium, and culturing the iPSCs for about 2 days in about 37C and in the presence of about 5% CO2 to generate mesoderm cells;(ii) differentiating the mesoderm cells into vascular progenitor cells by: removing the mesoderm induction medium and adding vascular progenitor medium, and culturing the cells for about 2 days in about 37C and in the presence of about 5% CO2 to generate vascular progenitor cells;(iii) differentiating the vascular progenitor cells into iECs by: dissociating the vascular progenitor cells by using a first dissociation enzyme for about 5 minutes at 37C and in the presence of about 5% CO2, wherein the dissociation enzyme comprises an animal origin free enzyme that cleaves peptide bonds on the C-terminal sides of lysine and arginine; neutralizing the vascular progenitor cells by using basal endothelial cell growth medium MV2 plus about 10% human AB serum, spinning the vascular progenitor cell solution, removing the basal endothelial medium, and resuspending the vascular progenitor cells in GMP-grade iEC differentiation medium, wherein the human AB serum comprises human serum lacking antibodies against A and B blood-type antigens that was converted from Pooled Plasma (Human), Solvent / Detergent Treated; plating the vascular progenitor cells at about 10,000 cells / cm2with iEC differentiation medium onto a dish that was previously coated with 5ug / ml human recombinant laminin 421 in PBS Mg+ / Ca+ for about 2 hours at about 37C and in the presence of about 5% CO2, culturing the vascular progenitor cells at about 37C and in the presence of about 5% CO2 for about 7 days, feeding about every other day with iEC differentiation medium to generate iECs;(iv) further culturing the iECs by: dissociating the iECs by using animal origin free enzyme that cleaves peptide bonds on the C-terminal sides of lysine and arginine (IX) for about 5 minutes at about 37C and in the presence of about 5% CO2; neutralizing the iECs using by using basal endothelial cell growth medium MV2 plus 10% Human AB serum, spinning the4916-7926-95402 Page 28 of 47 065472-001029WOPTiEC solution, removing the basal endothelial medium, and resuspending the iECs in GMP-grade iEC differentiation medium, wherein the human AB serum comprises human serum lacking antibodies against A and B blood-type antigens that was converted from Pooled Plasma (Human), Solvent / Detergent Treated; plating the iECs at about 10,000 cells / cm2with iEC differentiation medium onto a dish that was previously coated with 5ug / ml human recombinant laminin 421 in PBS Mg+ / Ca+ for about 2 hours at about 37C and in the presence of about 5% CO2, culturing the iECs at about 37C and in the presence of about 5% CO2 for about 10 days, feeding about every other day with iEC medium, thereby generating iECs expressing CD31 and CD 144.

[0145] In various embodiments, the method can further comprise dissociating the iECs that are generated in step (iv).

[0146] In various embodiments, the method can further comprise providing plated iPSCs, wherein the plated iPSCs are made by: dissociating iPSCs with a cGMP enzyme-free human pluripotent stem cell selection and passaging reagent for 5 minutes and neutralizing the iPSCs with iPSC maintenance medium; triturating the iPSCs about 10-15 times to break large colonies of iPSCs to smaller colonies of iPSCs and to have a homogenous cell population that is about 60-200um diameter per iPSC colony; dissociating a subset of colony solution as single cells by using a dissociation solution, for 5 minutes at 37C water bath, wherein the dissociation solution comprises a cell detachment solution of proteolytic and collagenolytic enzymes and does not contain mammalian or bacterial derived products; neutralizing the dissociation solution by using a cGMP feeder-free iPSC maintenance medium, spinning the cell solution, removing the medium and resuspending the iPSCs in iPSC maintenance medium; removing laminin solution from a plating dish that previously coated with 5ug / ml human recombinant laminin 521 in PBS Mg+ / Ca+ for 2 hours in 37C and in the presence of 5% CO2; adding cGMP feeder-free iPSC maintenance medium to the plating dish; adding about 2000 iPSCs / cm2to the plating dish and culturing at 37C and in the presence of 5% CO2; changing the cGMP feeder-free iPSC maintenance medium daily for an additional 2 days.

[0147] In various embodiments, the mesoderm induction medium can comprise a final concentration of about 6uM CHIR99021 and about 1:1000 Antibiotic- Antimycotic (PSA) in iPSC differentiation medium, wherein the iPSC differentiation medium comprises a defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages. In various embodiments, the mesoderm induction medium can comprise a final concentration of about 6uM CHIR99021 in iPSC differentiation medium, wherein the iPSC4916-7926-95402 Page 29 of 47 065472-001029WOPTdifferentiation medium comprises a defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages.

[0148] In various embodiments, the vascular progenitor medium can comprise final concentrations of about 25 ng / ml Bone Morphogenetic Protein 4 (BMP4), about 10 ng / ml FGF2, about 50 ng / ml VEGF165 and about 1:1000 Antibiotic-Antimycotic (PSA) in iPSC differentiation medium. In various embodiments, the vascular progenitor medium can comprise final concentrations of about 25 ng / ml Bone Morphogenetic Protein 4 (BMP4), about 10 ng / ml FGF2, and about 50 ng / ml VEGF165 in iPSC differentiation medium.

[0149] In various embodiments, the iEC differentiation medium can comprise Basal MV2, PSA, Human AB Serum (AB serum), Epidermal Growth Factor (EGF), Basic Fibroblast Growth Factor (FGF2), Long R3 Insulin-like Growth Factor (IGF-1), Vascular Endothelial Growth Factor 165 (VEGF 165), Ascorbic acid, and Hydrocortisone.

[0150] In various embodiments, the iEC differentiation medium can comprise Basal MV2, 1:1000 PSA, 0.1 ml / ml Human AB Serum (AB serum), 5 ng / ml Epidermal Growth Factor (EGF), 10 ng / ml Basic Fibroblast Growth Factor (FGF2), 20 ng / ml Long R3 Insulin-like Growth Factor (IGF-1), 260 ng / ml Vascular Endothelial Growth Factor 165 (VEGF 165), 1 ug / ml Ascorbic acid, and 0.2 ug / ml Hydrocortisone.

[0151] In various embodiments, the quantity is a clinically meaningful quantity.Routes of administration

[0152] In various embodiments, the compositions according to the invention may be formulated for delivery via any route of administration. “Route of administration” may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, oral, transmucosal, transdermal or parenteral.

[0153] Transdermal” administration may be accomplished using a transdermal patch, gel and the like.

[0154] “Parenteral” refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrastemal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection.4916-7926-95402 Page 30 of 47 065472-001029WOPT

[0155] Via the topical route, the compositions based on compounds according to the invention may be formulated for treating the skin and mucous membranes and are in the form of gels, patches, grafts, wound dressing and the like.Kits

[0156] The present invention is also directed to a kit to treat a disease or condition described herein. The kit is an assemblage of materials or components, including at least one of the inventive compositions. Thus, in some embodiments the kit contains a composition including modular composition with patterned cells, as described herein.

[0157] The exact nature of the components configured in the inventive kit depends on its intended purpose. In one embodiment, the kit is configured particularly for the purpose of treating mammalian subjects. In another embodiment, the kit is configured particularly for the purpose of treating human subjects. In further embodiments, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, domestic animals, and laboratory animals.

[0158] Instructions for use may be included in the kit. “Instructions for use” typically include a tangible expression describing the technique to be employed in using the components of the kit to effect a desired outcome, such as to treat the disease or condition. Optionally, the kit also contains other useful components, such as, diluents, buffers, pharmaceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, bandaging materials or other useful paraphernalia as will be readily recognized by those of skill in the art.

[0159] The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. For example, the kit can comprise cryopreserved GelMA microgels pre-loaded with cytokines and pro-angiogenic cues and cryopreserved hiPSC-ECs. In another example, the kit can comprise pre-assembled GelMA- iPSC-EC composite hydrogel in sterile, implantable format to use for vascular grafting or as wound bed. The components are typically contained in suitable packaging material(s). As employed herein, the phrase “packaging material” refers to one or more physical structures used to house the contents of the kit, such as inventive compositions and the like. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. As used herein, the term “package” refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the4916-7926-95402 Page 31 of 47 065472-001029WOPTindividual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of an inventive modular composition with patterned cells. The packaging material generally has an external label which indicates the contents and / or purpose of the kit and / or its components.EXAMPLES

[0160] The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.Example 1Materials and methodsSynthesis of GelMA

[0161] GelMA was synthesized as reported previously. (Moghimi, N. et al., Development of bioactive short fibers reinforced printable hydrogel with tunable mechanical and osteogenic properties for bone repair. Journal of Materials Chemistry B 2024. Zatorski, J. M. et al., Quantification of fractional and absolute functionalization of gelatin hydrogels by optimized ninhydrin assay and 1 H NMR. Analytical and bioanalytical chemistry 2020, 412, 6211-6220.) Briefly, 10 gm of Gelatin Type A (Sigma Aldrich) was dissolved in carbonate buffer (pH: 9.0) at 40°C under constant magnetic stirring. Following complete dissolution after 2 hours, methacrylic anhydride (1 ml, Sigma Aldrich) was added gradually, and the reaction was allowed to proceed for 4 hours. The reaction was terminated by adjusting the pH to 7.0, and the solution underwent dialysis for 3 days using a 14 kDa dialysis membrane, with water changes occurring every 12 hours. Subsequently, the solution was lyophilized for 2 days to yield GelMA flakes, which were stored at -20 °C for future applications. The degree of functionalization (DoF) was quantified using a Ninhydrin assay. (Figure 23).Preparation of photoresins

[0162] Photoresins were formulated using either pure GelMA (7.5% w / v) or by blending GelMA with varying concentrations of PEGDA (Mn 750 Da, Sigma Aldrich). Specifically, GelMA, PEGDA, and 0.1% Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP, Sigma Aldrich) were dissolved in PBS at 40 °C for 30 minutes to achieve a homogeneous solution. Three distinct types of photoresins were prepared for the fabrication of4916-7926-95402 Page 32 of 47 065472-001029WOPTmicrogels: GelMA at 7.5% w / v; GelMA at 7.5% w / v combined with PEGDA at 2.5% w / v (denoted as P2.5G7.5); and GelMA at 7.5% w / v combined with PEGDA at 5% w / v (denoted as P5G7.5).FLight based fabrication of microgels

[0163] Microgels were fabricated using FLight setup that transmitted 405 nm light from an LED to a Texas Instruments DMD (Light Crafter 4500), illuminating a cubic vial (51 mm x 51 mm) filled with photoactive resins using various geometrical light patterns, achieving a maximum irradiance of 20-25 mW / cm2at the image plane. Different microgel shapes were designed using a greyscale format, where each shape corresponds to 100% light intensity. The designed images were converted to JPEG format for projection. The photoactive resins were poured into cubic vials and maintained at 4 °C to allow thermal gelation, after which they were placed on the print platform where the projector selectively crosslinked the resin at specific locations, forming distinct microgel shapes. This thermal gelation facilitated high OMI, enabling the formation of fibrillated structures. After 50 seconds of exposure, the cubic vials were stored at 37 °C to reverse thermal gelation and to remove uncrosslinked photoactive resin, with microgels collected using a 100 pm cell strainer for subsequent processing. For fabrication with cells (1.5 million / ml of photoresin), all protocols were conducted in a sterile environment, and the photoresin was mixed with cells prior to being placed in the cubic vial. A 7.5% GelMA-based bioink was employed for all cell-related experiments.Rheological evaluation of Photo Resins

[0164] For rheological analysis, photoresin discs (8 mm diameter, 1mm thickness) were fabricated using FLight. Rheological properties were evaluated using frequency sweep analysis between 0.1 to 10 Hz at 1 mm plate gapping using MCR Anton Paar. G’ values were utilized for stiffness calculations.Injectability evaluation

[0165] To assess the injectability of the microgels, microgels measuring -500 pm were fabricated and collected using a cell strainer. The collected microgels were then transferred into a 5 ml syringe and injected through a 21G blunt nozzle. To visualize the microgels within the channel, transparent 21G glass channels were employed, and images were captured using a fluorescent microscope (Keyence Inverted Fluorescence Microscope, Trinocular, Halogen Light).Fabrication of MAPs

[0166] For fabrication of MAPs, collected microgels (rods and squares) were resuspended in 0.1% LAP solution, centrifuged at 10000 rpm for packing, and placed in4916-7926-95402 Page 33 of 47 065472-001029WOPTPoly dimethyl siloxane (PDMS) molds (2 mm thick, 8 mm diameter). They were further stabilized by exposure to 405 nm light, and the fabricated MAP discs were then utilized for cell seeding. All procedures were performed in a sterile environment. Rhodamine solution (0.01%) was used for microgel fabrication for their easy observation under a confocal microscope.MAP characterization

[0167] MAP discs were synthesized to evaluate the stiffness of MAPs composed of rods and squares, as stated above. Rheological properties were evaluated using frequency sweep analysis between 0.1 to 10 Hz at 1mm plate gapping using an MCR Anton Paar Plate rheometer. G’ values were utilized for stiffness calculations. For porosity calculation, 2D slices from z-stacked images were obtained and the porosity was calculated as reported previously20. For cell infiltration in MAPs, cell-seeded MAPs (microgels tracked with FITC, HDF cells tracked green, 20000 cells / MAP disc) were imaged at different time points. 3D images were used to calculate depth of penetration. At each time point, at least 3 samples were imaged, and at least 3 independent experiments were performed.Fabrication of modular hydrogel sheets

[0168] To fabricate modular hydrogel sheets, a design consisting of microsquares (approximately 500 pm) was initially created in greyscale format. The spacing between adjacent microsquares was maintained at 200-400 pm, resulting in microchannels of similar dimensions. GelMA photoresins were poured into rectangular vials and kept at 4 °C to promote physical gelation. The vials were then exposed to a FLight setup to selectively crosslink the projected micro-areas, yielding hydrogel sheets. After exposure, the embedded hydrogel sheets were retrieved by melting the photoresin at 37 °C for 10 minutes. The resulting sheets were thoroughly washed with PBS and stored for future use.

[0169] For seeding iECs onto modular scaffolds, on Day 11 of the experiment, iECs were gently added in a drop-wise manner at a density of 100,000 cells per 10 ml in iEC differentiation medium. After a 30-minute incubation, the plate was filled with additional differentiation medium. The iECs were fed every other day, and cell analysis was conducted on Days 3 and 7 post-seeding. The viability of the iECs was assessed using the LIVE / DEAD® Viability / Cytotoxicity Kit (Thermo Fisher Scientific), which differentiates between live and dead cells. Live cells were identified by green fluorescence from Calcein-AM, while red fluorescence from ethidium homodimer- 1 indicated cell death.

[0170] To characterize the seeded cells, immunostaining was performed. The iECs were first fixed with 4% paraformaldehyde. After washing with PBS, the cells were blocked and permeabilized in a PBS / 0.1% Triton-X (Bio-Rad) and donkey serum (Millipore) solution4916-7926-95402 Page 34 of 47 065472-001029WOPTfor 1 hour at room temperature. Immunostaining was carried out using antibodies against the endothelial marker CD31 (Cell Signaling) at a dilution of 1 : 100 for 1 hour at room temperature. Following thorough washing with 0.1% Tween 20 (Thermo Fisher) in PBS, the cells were incubated with secondary antibodies targeting mouse (excitation wavelength 647) for 1 hour at room temperature. Finally, the cell nuclei were stained with DAPI.Fabrication of Janus assembly

[0171] GelMA membranes were initially fabricated using the FLight technique and subsequently seeded with RPEs at a density of 2700 cells per membrane. These membranes were cultured for 14 days to develop a mature epithelial layer (indicated by green tracking). After this period, fibrillated microrods were biofabricated atop the previously constructed GelMA membranes, which contained encapsulated PRs at a concentration of 1 million cells / ml derived from dissociated retinal organoids. The cell-loaded Janus Assembly was then maintained in culture and monitored over a span of 7 days.Cell cultureHDF and C2C12

[0172] HDFs were cultured in Dulbecco’s Modified Eagle Medium supplemented with GlutaMAX™ (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco) at 37 °C in a humidified atmosphere with 5% CO2. Once the cells reached confluency, they were trypsinized using TrypLE™ (Gibco) for use in subsequent experiments. Similar protocols were employed for C2C12 cells.Human iPSCs and iECs culture

[0173] iECs were generously provided by Cedars-Sinai Biomanufacturing Center. The iEC differentiation methodology has been previously documented. In brief, undifferentiated iPSCs, originally reprogrammed from healthy donor peripheral blood mononuclear cells (PBMCs) were seeded and cultured in mTeSR+ medium (STEMCELL Technologies) on recombinant human laminin 521 (BioLamina)-coated plates. The differentiation of iECs from iPSCs was conducted over three distinct phases. During phase 1, iPSCs were induced towards mesodermal lineage using CHIR99021 (Xcess Bio) for a period of 2 days. Subsequently, vascular progenitors were generated through treatment with a combination of bone morphogenic protein 4 (BMP4; R&D Systems), fibroblast growth factor 2 (FGF2; PeproTech), and vascular endothelial growth factor (VEGF165; PeproTech) in STEMdiffAPEL2 (STEMCELL Technologies) for an additional 2 days during phase 2. Finally, iECs were replated onto recombinant laminin 421 (BioLamina)-coated plates and cultured in EC growth medium MV2 (ECGM-MV2; PromoCell) supplemented with VEGF165 to facilitate4916-7926-95402 Page 35 of 47 065472-001029WOPTendothelial cell induction over a period of 7 days, with media changes performed every other day.RPEs and PRsStem Cells and RPE Differentiation

[0174] The differentiation of H9 human embryonic stem cells (hESCs) into RPE cells and the generation of retinal organoids entail several crucial steps. The hESCs, sourced from WiCell (Madison), were initially cultured in mTeSRl medium supplied by STEMCELL Technologies. Over a period of 12 weeks, these cells underwent differentiation into RPE cells in XVIVO 10 medium. (Lonza). The pigmented RPE-like cells that developed were then enriched through mechanical isolation. Following isolation, these cells underwent further processing, including dissociation with TrypLE (Life Technologies) and subsequent culture on plates coated with human vitronectin (AMS Biotechnology) in XVIVO 10 medium. Cells at passage 3 were then prepared for additional experiments.

[0175] To generate retinal organoids, hESCs were genetically modified to express a green fluorescent protein (GFP) tagged CRX gene, a generous contribution from Majlinda Lako at Newcastle University, UK. The CRX-GFP cells, derived from H9 (NIH 0043), were cultured at the University of Southern California (USC, Los Angeles, CA) under a material transfer agreement with the University of Newcastle's Biosciences Institute. The CRX gene encodes the cone-rod homeobox protein, specifically expressed in photoreceptor cells. The CRX-GFP H9 cells were maintained in mTeSRl medium (STEMCELL Technologies) and passaged at 80% confluency using ReLeSR (STEMCELL Technologies). These media and supplements were selected for their effectiveness in supporting cell growth and differentiation. Cells were expanded on plates coated with BD GFR Matrigel and incubated in a humidified atmosphere of 95% oxygen, 5% CO2, and 37 °C.

[0176] When cultures became confluent, they were dissociated into single cells using Accutase (Nacalai Inc) to initiate retinal organoid differentiation. The cells were then transferred to 800-pm micro-well EZSPHERE 6-well plates and centrifuged at 100g for 3 minutes, allowing embryoid bodies (EBs) to form over the first 7 days. On day 8, the EBs were transferred to culture dishes coated with 1% growth factor-reduced Matrigel (Coming). The medium was gradually shifted from mTeSRl to neural induction media (NIM) containing DMEMZF12 (1:1) (Gibco), 1% N2 supplement (Gibco), lx non-essential amino acids (NEAA) (Gibco), lx L-glutamine (Gibco), and 2 pg / ml heparin (Sigma-Aldrich), with daily media changes. These formulations were selected for their capacity to induce neural differentiation. The EBs adhered and began differentiating into eye field structures. From days 19 to 41, the4916-7926-95402 Page 36 of 47 065472-001029WOPTmedia was switched to NIM supplemented with 2% B27 supplement (minus vitamin A, Gibco), lx NEAA, lx L-glutamine, and 2 mg / ml heparin (Sigma). These supplements were chosen to enhance cell survival and growth. Between days 40 and 50, retinal eye fields were manually dissected from the dish and transferred to ultra-low attachment 24-well plates (Coming). From day 42 onwards, the organoids were cultured in DMEMZF12 (1:1) with 10% FBS, supplemented with 2% B27 Plus Supplement (Gibco), lx NEAA, lx L-glutamine, 2 pg / ml heparin, and 100 pM taurine (Sigma).Dissociation of Retinal Organoids

[0177] To dissociate the retinal organoids, we utilized advanced equipment and techniques. A papain solution (10 mg / mL) was prepared by diluting 1:100 in an activation buffer and incubated in an open tube in a cell culture incubator set to 7% CO2 for 30 minutes to activate the enzyme. The organoids were collected into a tube and washed with Hanks' Balanced Salt Solution (HBSS) prior to digestion. For dissociation, the organoids were incubated at 37 °C with the activated papain solution for 15 minutes, with agitation every two minutes. The organoids were then pipetted to resuspend the cell clusters, washed with OC media, and strained through a 0.4-pm cell strainer.Cell viability, Proliferation, and cytoskeleton staining

[0178] Cell viability was assessed using calcein AM (1 pM, Invitrogen™) and ethidium homodimer (1 pM, Invitrogen™) staining at room temperature for 20 minutes. Following staining, the samples were washed with IX DPBS and visualized using confocal microscopy (Zeiss LSM 700) at 488 nm for calcein AM (green, indicating viable cells) and 561 nm for ethidium homodimer (red, indicating dead cells).

[0179] Cell proliferation was quantified using PrestoBlue™ cell viability reagent at various time points. Briefly, a working solution of PrestoBlue™ (Invitrogen™) was prepared by diluting it 1:10 with complete media according to the manufacturer's protocol. The complete media was removed from the samples, and PrestoBlue™ solution was added before incubating for 3 hours at 37 °C in a 5% CO2 incubator. After incubation, the solution was collected from each sample, and absorbance was measured at 570 nm and 600 nm using a Varioskan Lux plate reader (Thermo Fisher Scientific). The cell proliferation rate, which is directly proportional to the percentage of dye reduction, was calculated from the absorbance data and presented as a bar graph with standard deviations, using triplicate samples for each time point.

[0180] Cell morphology was examined through actin staining. At specified time points, cells were fixed overnight at 4 °C with 4% formaldehyde solution, then washed with IX DPBS and treated with 0.1% Triton X-100 for 10 minutes. These permeabilized samples were washed4916-7926-95402 Page 37 of 47 065472-001029WOPTthree times with IX DPBS and blocked with 1% bovine serum albumin for 30 minutes, followed by additional washing with IX DPBS. Alexa Fluor™ 594 phalloidin (Invitrogen™) was then added for a 30-minute incubation at room temperature. The fluorescently stained microgels were washed with IX DPBS, and the nuclei were stained with DAPI (Invitrogen™) for 5 minutes. Finally, the fluorescently stained microgels were imaged using confocal microscopy (Zeiss LSM 700) for the fluorescent channels at 594 nm (cytoskeleton, red) and 405 nm (nuclei, blue).IF staining

[0181] For C2C12 staining, microrods loaded with cells were fixed for 20 minutes in a 4% paraformaldehyde solution after 4 days of culture in differentiation media. This fixation was followed by a 10-minute permeabilization step using Triton X-100 and a 30-minute blocking step with a 1% BSA solution. The blocked samples were then incubated overnight at 4 °C with the primary antibody Anti -Desmin [ab 15200, Abeam] to assess the formation of heavy chain myotubes. After overnight incubation, the samples were treated with a secondary antibody (Goat Anti-rabbit Alexa Fluor 488, Abeam) for 1 hour. Following this incubation, the samples were washed three times with PBS, counterstained with DAPI, and observed under a confocal microscope. For Myosin Heavy Chain staining (MYHC) similar protocol was adopted at 7 days post induction in differentiation media. Primary antibody used was anti-myosin (MYH, ab37484, host species mouse). Secondary antibody was selected based on primary (Rabbit anti-mouse, Alexa Fluor 488, Invitrogen).

[0182] For staining of CD31, Recoverin, and ZO-1 in modular assemblies, a similar procedure was followed. The primary antibodies used included Rabbit polyclonal to CD31 (ab28364, Abeam), Rabbit polyclonal Recoverin antibody (6a55cd6, Abeam), and ZO-1 Monoclonal Antibody (ZO1-1A12, Abeam) for CD31, Recoverin, and ZO-1, respectively. The secondary antibodies were selected based on the source of the primary antibodies.Subcutaneous implantation

[0183] All surgeries were conducted in an aesthetic environment, adhering to standard ethical protocols. Briefly, male C57B1 / 6 mice aged 6 months were anesthetized with isoflurane vapors. The mouse abdomen was sterilized with 70% isopropyl alcohol, and two 200 pl plugs were injected into the abdomen using a 21G syringe and forceps. A total of 4 animals were used for each injection, with two plugs injected into each animal (left and right cavities), resulting in 8 subcutaneous injections per shape across the four animals. Following microgel4916-7926-95402 Page 38 of 47 065472-001029WOPTplugs were injected: 1. Rod-shaped microgels, 2. Rod-shaped microgels with QK peptide, 3. Square-shaped microgels, and 4. Square-shaped microgels with QK peptide. After 2 weeks, the animals were euthanized, and the tissue plugs were isolated and embedded in OCT for cryosectioning. Hematoxylin and eosin (H&E) staining was performed on the cryosections from the isolated plugs to assess tissue infiltration, and sections were also stained for CD31 to evaluate neovascularization following standard protocols.Statistical analysis

[0184] Quantitative variables were evaluated for normality using statistical tests such as Shapiro-Wilk or Kolmogorov-Smirnov, along with descriptive statistics and graphical analyses, including QQ plots. For parametric data, analysis of variance (ANOVA, one-way or two-way) was conducted, followed by Tukey’s post hoc test to assess differences between groups and time points in both in vitro and in vivo experiments. Unpaired t-tests were used for comparisons involving two groups. Non-parametric data were analyzed using the Kruskal-Wallis test to examine differences between groups and time points. For non-parametric comparisons between two groups, the Mann- Whitney test was applied for unpaired samples. Statistical significance was set at p < 0.05, with significance levels indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). All statistical analyses were performed using GraphPad Prism version 9 for Windows.

[0185] Various embodiments of the invention are described above in the Detailed Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and / or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventors that the words and phrases in the specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

[0186] The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the invention and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various modifications as are4916-7926-95402 Page 39 of 47 065472-001029WOPTsuited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

[0187] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of’ or “consisting essentially of.”

[0188] Unless stated otherwise, the terms “a” and “an” and “the” and similar references used in the context of describing a particular embodiment of the application (especially in the context of claims) may be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein may be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the application and does not pose a limitation on the scope of the application otherwise claimed. The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” No language in the specification should be construed as indicating any non-claimed element essential to the practice of the application.4916-7926-95402 Page 40 of 47 065472-001029WOPT

[0189] “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

[0190] Groupings of alternative elements or embodiments of the present disclosure disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.4916-7926-95402 Page 41 of 47 065472-001029WOPT

Claims

WHAT IS CLAIMED IS:

1. A method of producing a modular composition with patterned cells, comprising:providing a hydrogel composition having aligned fibrillar structures, interconnected channels and modular scaffolds;seeding cells of a first cell type onto the modular scaffolds of the hydrogel composition;adding additional cell culture medium to the hydrogel composition; and culturing the cells of the first cell type in the hydrogel composition to generate the modular composition with patterned cells.

2. The method of claim 1, wherein the hydrogel composition further comprises cells of a second cell type embedded in micromodules in the hydrogel composition.

3. The method of claim 1, further comprising seeding cells of a second cell type in micromodules in the hydrogel composition.

4. The method of any one of claims 1-3, wherein seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 10,000-1,000,000 cells per 10 ml cell culture medium.

5. The method of any one of claims 1-3, wherein seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 25,000-500,000 cells per 10 ml cell culture medium.

6. The method of any one of claims 1-3, wherein seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 50,000-150,000 cells per 10 ml cell culture medium.

7. The method of any one of claims 1-3, wherein seeding cells of the first cell type comprises seeding the cells of the first cell type at a density of about 100,000 cells per 10 ml cell culture medium.

8. The method of any one of claims 1-7, wherein the cell culture medium is differentiation medium.

9. The method of any one of claims 1-8, wherein the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 10-120 minutes incubation time after seeding the cells of the first cell type.

10. The method of any one of claims 1-8, wherein the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture4916-7926-95402 Page 42 of 47 065472-001029WOPTmedium after about 15-60 minutes incubation time after seeding the cells of the first cell type.

11. The method of any one of claims 1-8, wherein the adding additional cell culture medium to the hydrogel composition comprising adding the additional cell culture medium after about 30 minutes incubation time after seeding the cells of the first cell type- 12. The method of any one of claims 1-11, wherein the additional cell culture medium is differentiation medium.

13. The method of any one of claims 1-12,wherein seeding cells of the first cell type onto the hydrogel composition comprises adding endothelial cells derived from induced pluripotent stem cells (iECs) to the hydrogel composition a drop-wise manner at a density of about 100,000 cells per 10 ml in iEC differentiation medium;wherein adding additional cell culture medium to the hydrogel composition comprises adding additional iEC differentiation medium after about 30 minutes; and wherein the the hydrogel composition is a hydrogel sheet comprising interconnected channels.

14. The method of any one of claims 1-12, wherein the cells of the first cell type are iPSC, endothelial cells derived from induced pluripotent stem cells (iECs), islet cells, smooth muscle cells, or pericytes.

15. The method of any one of claims 1-12, wherein the cells of the first cell type are endothelial cells derived from induced pluripotent stem cells (iECs).

16. The method of any one of claims 1-15, wherein the interconnected channels have 50- 800 pm dimensions.

17. The method of any one of claims 1-15, wherein the interconnected channels have 100- 600 pm dimensions.

18. The method of any one of claims 1-15, wherein the interconnected channels have 200- 400 pm dimensions.

19. The method of any one of claims 1-18, wherein the cells of the first cell type grow in the interconnected channels.

20. The method of any one of claims 1-19, wherein cells of the first cell type restrict themselves to the interconnected channels generating modular sheets with patterned cells.4916-7926-95402 Page 43 of 47 065472-001029WOPT21. The method of any one of claims 1-20, wherein the hydrogel composition is a hydrogel sheet.

22. The method of any one of claims 1-21, wherein the hydrogel composition is configured to be in a shape of a graft or an implant.

23. The method of any one of claims 1-22, wherein the hydrogel composition comprises pure GelMA, or GelMA and PGDA.

24. The method of any one of claims 1-22,wherein the hydrogel composition is fabricated from a photoresin comprising GelMA (5-10% w / v), orwherein the hydrogel composition is fabricated from a photoresin comprising PEGDA (1-4% w / v) and GelMA (5-10% w / v), orwherein the hydrogel composition is fabricated from a photoresin comprising PEGDA (3.5-6.5% w / v) and GelMA(7.5% w / v).

25. The method of any one of claims 1-22,wherein the hydrogel composition is fabricated from a photoresin comprising GelMA (7.5% w / v, G7.5), orwherein the hydrogel composition is fabricated from a photoresin comprising PEGDA (2.5% w / v, P2.5) and GelMA(7.5% w / v, G7.5), orwherein the hydrogel composition is fabricated from a photoresin comprising PEGDA (5.0% w / v, P5.0) and GelMA(7.5% w / v, G7.5).

26. The method of any one of claims 1-22, wherein the hydrogel composition is made by a method comprising:designing microsquares on a sheet having 100-600 pm spacings to create microchannels having 100-600 pm dimensions;pouring a photoresin into the microchannels and keeping the sheet at about 2- 10°C allow for physical gelation,wherein the photoresin comprises pure GelMA or wherein the photoresin comprises GelMA and PGDA;exposing the microchannels to about 390-420 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet;melting the photoresin in the embedded hydrogel sheet at about 30-42°C for about 5-15 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.4916-7926-95402 Page 44 of 47 065472-001029WOPT27. The method of any one of claims 1-22, wherein the hydrogel composition is made by a method comprising:designing microsquares on a sheet having 200-400 pm spacings to create microchannels having 200-400 pm dimensions;pouring a photoresin into the microchannels and keeping the sheet at about 4°C allow for physical gelation,wherein the photoresin comprises pure GelMA or wherein the photoresin comprises GelMA and PGDA;exposing the microchannels to about 405 nm light having a geometrical light pattern at a maximum irradiance of 20-25 mW / cm2to selectively crosslink the projected micro areas to produce an embedded hydrogel sheet;melting the photoresin in the embedded hydrogel sheet at about 37°C for about 10 minutes to retrieve the embedded hydrogel sheet and produce the hydrogel sheet.

28. The method of any one of claims 1-27, wherein the micromodules are microgels in a size range of about 100 pm to 900 pm.

29. The method of any one of claims 1-27, wherein the micromodules are microgels in a size range of about 100 pm to 600 pm.

30. The method of any one of claims 1-27, wherein the micromodules are microgels in a size range of about 200 pm to 400 pm.

31. The method of any one of claims 1-30, wherein the micromodules are microgel that are rod-shaped, cube-shaped, cuboid-shaped, ellipsoid-shaped, triangle-shaped, star shaped, or combinations thereof.

32. The method of any one of claims 1-31, wherein the cells of the second cell type are islet cells, mesenchymal stem cells (MSCs), smooth muscle cells, or pericytes.

33. A composition comprising cells of the first cell type embedded in a modular composition with patterned cells produced by the method of any one of claims 1-32.

34. The composition of claim 33, wherein the cells of the first cell type are endothelial cells derived from induced pluripotent stem cells (iECs).

35. The composition of claim 34, wherein the iECs are in the interconnected channels of the modular composition with patterned cells.

36. The composition of any one of claims 33-35, further comprising cells of the second cell type embedded in a modular composition with patterned cells produced by the method of any one of claims 2-32.4916-7926-95402 Page 45 of 47 065472-001029WOPT37. The composition of claim 36, wherein the cells of the second cell type are in the micromodules of the modular composition with patterned cells.

38. The composition of any one of claims 33-37, wherein the modular composition with patterned cells is a patch.

39. The composition of claim 38, wherein the patch comprises:islet cells in the micromodules of the modular composition with patterned cells and iECs in the interconnected channels of the modular composition with patterned cells.

40. The composition of any one of claims 33-37, wherein the modular composition with patterned cells is a vascular graft.

41. The composition of claim 38, wherein the vascular graft comprises iECs in interconnected channels of the modular composition with patterned cells.

42. The composition of any one of claims 33-37, wherein the modular composition with patterned cells is a wound dressing.

43. The method of claim 42, wherein the wound dressing comprises iECs in the interconnected channels of the modular composition with patterned cells and MSCs in the micromodules of the modular composition with patterned cells.

44. A method of treating a disease or condition, comprising:administering the modular composition with patterned cells of any one of claims 33-43 to a subject afflicted with the disease or condition.

45. The method of claim 44, wherein the disease or condition is critical limb threatening ischemia, peripheral artery disease, diabetic retinopathy, pulmonary hypertension, Ischemic heart disease, chronic wound, bum, stroke, osteonecrosis (avascular necrosis), bone fracture, or non-union bone fracture.

46. The method of claim 44 or claim 45, wherein the cells of the first cell type are iECs.

47. The method of claim 44, wherein the condition is a wound and the cells of the first cell type are iECs.

48. The method of claim 44, wherein the condition is a bum wound and the cells of the first cell type are iECs.

49. The method of claim 44, wherein the disease or condition is diabetes and the cells of the first cell type are iECs and the cells of the second cell type are islet cells.

50. The method of any one of claims 44-49 wherein the cells of the second cell type are smooth muscle cells.4916-7926-95402 Page 46 of 47 065472-001029WOPT